DPAGT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL24164783	0.89	6/20
SCHEMBL24165556	0.89	6/20
SCHEMBL26628858	0.89	6/20
SCHEMBL26628860	0.89	6/20
SCHEMBL26742327	0.89	6/20
SCHEMBL26628854	0.79	6/20
SCHEMBL26628856	0.79	6/20
SCHEMBL32681957	0.74	6/20
SCHEMBL14598984	0.72	6/20
SCHEMBL13618329	0.71	6/20
SCHEMBL13618320	0.65	6/20
SCHEMBL26741959	0.65	6/20
SCHEMBL26741960	0.65	6/20
SCHEMBL24164786	0.61	6/20
SCHEMBL24165043	0.61	6/20
SCHEMBL14628987	0.61	6/20
SCHEMBL14628971	0.61	6/20
SCHEMBL32681956	0.60	6/20
Capuramycin (SCHEMBL14598937)	0.92	5/20
Capuramycin (SCHEMBL15472874)	0.92	5/20

Clinical trials — most relevant to DPAGT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients	PHASE2	ENROLLING_BY_INVITATION
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer	PHASE2	UNKNOWN
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer	PHASE1	COMPLETED
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers	PHASE1	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study	nan	RECRUITING
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network	nan	RECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Identification and Characterization of Monogenic Diabetes	nan	COMPLETED
Personalised Therapeutics @LUMC	nan	ACTIVE_NOT_RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects	nan	UNKNOWN
Genetics and Psychopathology in the 22q11 Deletion Syndrome	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Chest Wall Deformities in Children - Epidemiological Data	nan	COMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte	nan	COMPLETED
Markers and Mechanisms of Macrovascular Disease in IDDM	nan	COMPLETED
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan	nan	ENROLLING_BY_INVITATION
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)	nan	RECRUITING
The Natural History of Sialidosis Type I	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a DPAGT1 binder may also engage these)

Protein	Name	Similarity
P24140	—	1.000	P24140 →
P42867	—	1.000	P42867 →
Q5EA65	—	1.000	Q5EA65 →
P23338	—	1.000	P23338 →
Q6AXM5	—	0.963	Q6AXM5 →
Q8BGS7	—	0.962	Q8BGS7 →
CEPT1	Choline/ethanolaminephosphotransferase 1	0.962	landscape →
Q7ZYQ3	—	0.960	Q7ZYQ3 →
Q5ZKD1	—	0.958	Q5ZKD1 →
Q28H54	—	0.957	Q28H54 →
Q99L43	—	0.952	Q99L43 →
Q91XU8	—	0.952	Q91XU8 →
CDS2	Phosphatidate cytidylyltransferase 2	0.952	landscape →
SELENOI	Ethanolaminephosphotransferase 1	0.951	landscape →
Q66H21	—	0.951	Q66H21 →
Q8C025	—	0.951	Q8C025 →
Q17QM4	—	0.950	Q17QM4 →
A0JNC1	—	0.947	A0JNC1 →
Q1LZE6	—	0.947	Q1LZE6 →
Q5ZHQ5	—	0.945	Q5ZHQ5 →
Q92903	—	0.945	Q92903 →
P49282	—	0.944	P49282 →
Q80TA1	—	0.944	Q80TA1 →
O35052	—	0.943	O35052 →
ZMPSTE24	CAAX prenyl protease 1 homolog	0.942	landscape →
P98191	—	0.942	P98191 →
Q5NV96	—	0.941	Q5NV96 →
Q8WUD6	—	0.941	Q8WUD6 →
Q9LDU6	—	0.940	Q9LDU6 →
Q4KLV1	—	0.940	Q4KLV1 →